Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
BACKGROUND/AIMS: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment.
METHODS: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab. RNA-seq from blood samples was analyzed using the DESeq2 library by comparing responders and non-responders to anti-TNF drugs.
RESULTS: Bioinformatic analyses unveiled 102 differentially expressed genes, with 99 genes exhibiting higher expression in responders compared to non-responders prior to the initiation of anti-TNF therapy. Functional enrichment analyses highlighted defense response to Gram-negative bacteria (FDR = 2.3 ×10-7) as the most significant biological processes, and hemoglobin binding (FDR = 0.002), as the most significant molecular function. Gene Set Enrichment Analysis (GSEA) revealed notable enrichment in transcriptional misregulation in cancer (FDR = 0.016). Notably, 13 genes (CEACAM8, CEACAM6, CILP2, COL17A1, OLFM4, INHBA, LCN2, LTF, MMP8, DEFA4, PRTN3, AZU1, and ELANE) were selected for validation, and a consistent trend of increased expression in responders prior to drug administration was observed for most of these genes, with findings for 4 of them being statistically significant (CEACAM8, LCN2, LTF2, and PRTN3).
CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 173(2024) vom: 11. März, Seite 116299 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salvador-Martín, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116299 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368915042 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368915042 | ||
| 003 | DE-627 | ||
| 005 | 20240329000609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116299 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM368915042 | ||
| 035 | |a (NLM)38401525 | ||
| 035 | |a (PII)S0753-3322(24)00180-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salvador-Martín, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a BACKGROUND/AIMS: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment | ||
| 520 | |a METHODS: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab. RNA-seq from blood samples was analyzed using the DESeq2 library by comparing responders and non-responders to anti-TNF drugs | ||
| 520 | |a RESULTS: Bioinformatic analyses unveiled 102 differentially expressed genes, with 99 genes exhibiting higher expression in responders compared to non-responders prior to the initiation of anti-TNF therapy. Functional enrichment analyses highlighted defense response to Gram-negative bacteria (FDR = 2.3 ×10-7) as the most significant biological processes, and hemoglobin binding (FDR = 0.002), as the most significant molecular function. Gene Set Enrichment Analysis (GSEA) revealed notable enrichment in transcriptional misregulation in cancer (FDR = 0.016). Notably, 13 genes (CEACAM8, CEACAM6, CILP2, COL17A1, OLFM4, INHBA, LCN2, LTF, MMP8, DEFA4, PRTN3, AZU1, and ELANE) were selected for validation, and a consistent trend of increased expression in responders prior to drug administration was observed for most of these genes, with findings for 4 of them being statistically significant (CEACAM8, LCN2, LTF2, and PRTN3) | ||
| 520 | |a CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-TNF drugs | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a Pharmacogenomics | |
| 650 | 4 | |a RNA-seq | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Rubbini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Vellosillo, Perceval |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata-Cobo, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Velasco, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Palomino, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Clemente, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Segarra, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Álvarez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Lorenzo, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Moneo, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Montraveta, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Tolín, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Loverdos, Inés |e verfasserin |4 aut | |
| 700 | 1 | |a Fobelo, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Navas-López, Victor Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Magallares, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a García-Romero, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Peral, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Bossacoma, Ferrán |e verfasserin |4 aut | |
| 700 | 1 | |a Merino-Bohórquez, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Salcedo, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Dopazo, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Sanjurjo-Sáez, María |e verfasserin |4 aut | |
| 700 | 1 | |a López-Fernández, Luis A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 173(2024) vom: 11. März, Seite 116299 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:173 |g year:2024 |g day:11 |g month:03 |g pages:116299 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116299 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 173 |j 2024 |b 11 |c 03 |h 116299 | ||